DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
12/23/2025 12:00 PM • A class action lawsuit has been filed against DexCom, Inc. alleging that the company made unauthorized material design changes to its G6 and G7 glucose monitoring devices without FDA approval, rendering them less reliable and presenting health risks to users. The lawsuit covers investors who purchased DexCom securities between January 8, 2024 and September 17, 2025. The lead plaintiff deadline is December 26, 2025.
DXCM - The company faces a class action lawsuit alleging material misstatements regarding unauthorized FDA design changes to its glucose monitoring devices, reduced device reliability, health risks to users, and overstated product enhancements. These allegations expose DexCom to regulatory enforcement action, legal liability, reputational damage, and financial harm.
Investing.com • Timothy Fries